Dkt. 0575/50659/JPW/JML

## THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants David Baltimore et al.

08/813,323 Examiner: Eyler Serial No.

Filed March 10, 1997 Art Unit: 1642

TRUNCATED CRAF1 INHIBITS CD40 SIGNALING For

> 1185 Avenue of the Americas New York, New York 10036 July 28, 1998

> > inhibiting

CD40-

Assistant Commissioner for Patents Washington, D.C. 20231

SIR:

## SUPPLEMENTAL AMENDMENT

This Supplemental Amendment is submitted to supplement Amendment in Response to February 27, 1998 Office Action and Petition for a Two-Month Extension of Time which was filed on May 22, 1998 in connection with the above-identified application.

Please amend the subject application as follows:

## In the claims:

Please amend claim 1 as follows:

variant

A protein comprising CRAF1 truncated by --1. (amended) about 323 to about 414 amino acid residues at the amino terminus by at least 323 amino acid residues up to 414 amino acid residues, or a

thereof capable of

mediated cell activation.

## REMARKS

Claims 1-20 are pending. Applicants have hereinabove amended claim 1 more particularly point out the presently claimed Applicants contend that such amendment raises no issue of new matter. Support for this amendment may be found inter alia in the specification, for example, on page 8, line 3